Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
- PMID: 12393500
- DOI: 10.1182/blood-2002-08-2543
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Abstract
We have recently shown that proteasome inhibitor PS-341 induces apoptosis in drug-resistant multiple myeloma (MM) cells, inhibits binding of MM cells in the bone marrow microenvironment, and inhibits cytokines mediating MM cell growth, survival, drug resistance, and migration in vitro. PS-341 also inhibits human MM cell growth and prolongs survival in a SCID mouse model. Importantly, PS-341 has achieved remarkable clinical responses in patients with refractory relapsed MM. We here demonstrate molecular mechanisms whereby PS-341 mediates anti-MM activity by inducing p53 and MDM2 protein expression; inducing the phosphorylation (Ser15) of p53 protein; activating c-Jun NH(2)-terminal kinase (JNK), caspase-8, and caspase-3; and cleaving the DNA protein kinase catalytic subunit, ATM, and MDM2. Inhibition of JNK activity abrogates PS-341-induced MM cell death. These studies identify molecular targets of PS-341 and provide the rationale for the development of second-generation, more targeted therapies.
Similar articles
-
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.Oncogene. 2005 Apr 28;24(19):3121-9. doi: 10.1038/sj.onc.1208522. Oncogene. 2005. PMID: 15735676
-
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res. 2001 Apr 1;61(7):3071-6. Cancer Res. 2001. PMID: 11306489
-
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.Cancer Sci. 2004 Feb;95(2):176-80. doi: 10.1111/j.1349-7006.2004.tb03200.x. Cancer Sci. 2004. PMID: 14965369 Free PMC article.
-
Proteasome inhibition in cancer: development of PS-341.Semin Oncol. 2001 Dec;28(6):613-9. doi: 10.1016/s0093-7754(01)90034-x. Semin Oncol. 2001. PMID: 11740819 Review.
-
Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.Folia Med (Plovdiv). 2005;47(3-4):11-9. Folia Med (Plovdiv). 2005. PMID: 16761388 Review.
Cited by
-
Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.Biochem Biophys Res Commun. 2015 May 1;460(2):375-9. doi: 10.1016/j.bbrc.2015.03.041. Epub 2015 Mar 16. Biochem Biophys Res Commun. 2015. PMID: 25791477 Free PMC article.
-
Antileukemic Scalarane Sesterterpenoids and Meroditerpenoid from Carteriospongia (Phyllospongia) sp., Induce Apoptosis via Dual Inhibitory Effects on Topoisomerase II and Hsp90.Sci Rep. 2016 Oct 31;6:36170. doi: 10.1038/srep36170. Sci Rep. 2016. PMID: 27796344 Free PMC article.
-
Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors.PLoS One. 2013 Apr 11;8(4):e61438. doi: 10.1371/journal.pone.0061438. Print 2013. PLoS One. 2013. PMID: 23593480 Free PMC article.
-
IKK inhibition increases bortezomib effectiveness in ovarian cancer.Oncotarget. 2015 Sep 22;6(28):26347-58. doi: 10.18632/oncotarget.4713. Oncotarget. 2015. PMID: 26267322 Free PMC article.
-
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.Clin Cancer Res. 2009 Aug 15;15(16):5250-7. doi: 10.1158/1078-0432.CCR-08-2850. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671864 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
